Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0050865 |
| Name | tongue squamous cell carcinoma |
| Definition | A head and neck squamous cell carcinoma that is located_in the tongue. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma head and neck squamous cell carcinoma tongue squamous cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| TP53 mutant | Ceralasertib + Radiotherapy | tongue squamous cell carcinoma | sensitive | detail... |
| ATM I1453fs | Radiotherapy | tongue squamous cell carcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02993991 | Phase I | Durvalumab + Mocetinostat | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity | Withdrawn | CAN | 0 |
| NCT03799445 | Phase II | Ipilimumab + Nivolumab | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients with HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03829722 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Completed | USA | 0 |
| NCT03952585 | Phase II | Nivolumab Cisplatin | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT04116047 | Phase III | Cisplatin Cisplatin + Durvalumab | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE) | Active, not recruiting | IRL | GBR | 0 |
| NCT06919666 | Phase Ib/II | NT219 + Pembrolizumab Cetuximab + NT219 | NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |